In TALAPRO-2, patients were prospectively evaluated for HHR-related gene (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C) alterations in tumor tissue using FoundationOne CDx; a subsequent protocol amendment permitted prospective ctDNA testing using FoundationOne Liquid CDx [88]. This evidence concerns the gene CHEK2 and neoplasm.